Klotz Luisa, Hucke Stephanie, Thimm Dominik, Classen Sabine, Gaarz Andrea, Schultze Joachim, Edenhofer Frank, Kurts Christian, Klockgether Thomas, Limmer Andreas, Knolle Percy, Burgdorf Sven
Institutes of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Germany.
J Immunol. 2009 Jul 1;183(1):129-36. doi: 10.4049/jimmunol.0804260. Epub 2009 Jun 17.
Dendritic cells are able to take up exogenous Ags and present Ag-derived peptides on MHC class I molecules, a process termed cross-presentation. The mannose receptor (MR), an endocytic receptor expressed on a variety of APCs, has been demonstrated to target soluble Ags exclusively toward cross-presentation. In this study, we investigated the role of the murine nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor with immunomodulatory properties, in MR-mediated endocytosis and cross-presentation of the model Ag OVA. We could demonstrate both in vitro and in vivo that activation of PPARgamma resulted in increased MR expression, which in consequence led to enhanced MR-mediated endocytosis and elevated cross-presentation of soluble OVA. Concomitantly, activation of PPARgamma in dendritic cells induced up-regulation of the coinhibitory molecule B7H1, which, despite enhanced cross-presentation, caused an impaired activation of naive OVA-specific CD8(+) T cells and the induction of T cell tolerance. These data provide a mechanistic basis for the immunomodulatory action of PPARgamma which might open new possibilities in the development of therapeutic approaches aimed at the control of excessive immune responses, e.g., in T cell-mediated autoimmunity.
树突状细胞能够摄取外源性抗原,并在MHC I类分子上呈递抗原衍生肽,这一过程称为交叉呈递。甘露糖受体(MR)是一种在多种抗原呈递细胞上表达的内吞受体,已被证明能将可溶性抗原专门靶向交叉呈递。在本研究中,我们研究了小鼠核受体过氧化物酶体增殖物激活受体γ(PPARγ),一种具有免疫调节特性的配体激活转录因子,在MR介导的内吞作用和模型抗原OVA的交叉呈递中的作用。我们能够在体外和体内证明,PPARγ的激活导致MR表达增加,进而导致MR介导的内吞作用增强和可溶性OVA的交叉呈递升高。同时,树突状细胞中PPARγ的激活诱导了共抑制分子B7H1的上调,尽管交叉呈递增强,但导致初始OVA特异性CD8(+) T细胞的激活受损和T细胞耐受性的诱导。这些数据为PPARγ的免疫调节作用提供了机制基础,这可能为开发旨在控制过度免疫反应(例如在T细胞介导的自身免疫中)的治疗方法开辟新的可能性。